PK/PD - General Concepts
and Advanced Material - ADVANCED LEVEL


Printer friendly version

 

PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level)


Faculty:

Roger Jelliffe, MD
Irina Bondareva, Ph.D.
George Drusano, MD
Rüdiger Port, MD
Alexander Vinks, Ph.D
.

Target Participants:

This workshop, using minimal math, starts at a beginning level and progresses to an advanced level over 2 intensive days. It is intended for physicians, pharmacists, clinical chemists and biomedical scientists who have an interest in clinical therapeutic drug monitoring and optimal individualization of drug therapy for patient care and in population pharmacokinetic and pharmacodynamic research modeling techniques. Participants will be introduced to the USC*PACK software which can be used both for therapeutic drug monitoring as well as for parametric and nonparametric population PK/PD and physiological modeling.

Objectives and Expectations:

After this workshop, the participant should:

1. Be able to describe basic pharmacokinetic behavior of drugs in patients.
2. Be able to design optimal initial individualized dosage regimens of drugs to hit selected target goals most precisely.
3. Be able to enter and store patient data of doses, TDM serum concentrations, etc., and to make an individualized model of drug behavior in that patient.
4. Be able to develop an adjusted dosage regimen based on the patient's individualized model.
5. Understand how to apply these techniques to therapy with vancomycin, digoxin, anticonvulsants, and drugs for AIDS, cancer, and transplants.
6. Understand the basic ideas (not the math) behind parametric and nonparametric population PK/PD modeling.
7. Know how to determine the error polynomial for a drug assay, to fit each data point by an optimal measure of its credibility.
8. Understand Monte-Carlo simulation and its applications to clinical situations.
9. Understand the basic concepts of multiple model dosage design.

 

PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level)
Tuesday,
September 07th, 2004

Preliminary Program

Time
Topic

8:30

Beginning-Intermediate Clinical PK 1

The basic PK model – Roger Jelliffe
Its parameters: Ka, Kel, Vol, Clearance, Kcp, Kpc, T1/2

Dose individualization using target concentration strategy

                    An example for discussion: tracking drug behavior in unstable patients, with
changing doses, changing renal function, and ad-lib serum samples.

Basic PK building blocks

                    Evaluating renal function, especially in unstable patients
Evaluating lab assay errors, and then acting on them!
Evaluating other environmental errors

9:30

Beginning-Intermediate Clinical PK 2

Ways of fitting data - Roger Jelliffe
Linear regression on logs of data
Weighted nonlinear least squares
Maximum Aposteriori Probability (MAP) Bayesian fitting
The basic MAP Bayesian scenario
When to get data best - Alexander Vinks

10:30

Coffee

11:00

Beginning-Intermediate Population Modeling

               Parametric, iterative 2 stage Bayesian (IT2B) population modeling - Roger Jelliffe
Strengths and weaknesses of parametric models

11:45

Nonparametric Population Modeling - Roger Jelliffe

Its strengths and weaknesses
Unified approaches to population modeling

12:30

Multiple Model Dosage Design - Roger Jelliffe

13:00

Lunch

14:30

Intermediate PK – Tissue Distribution

                  Modeling diffusion in endocardial vegetations - Roger Jelliffe
                  Modeling bacterial growth and kill, and post-antibiotic effect

15:30

How to describe and build PD relationships for anti-infective drugs - George Drusano

16:00

Erythropoetin therapy in childhood renal anemia - Rüdiger Port

16:30

End

 

 

PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level)
Wednesday,
September 08th, 2004

Preliminary Program

Time
Topic

8:30

Advanced PK 3

Modeling linear and nonlinear antiepileptic drug  models - Irina Bondareva

9:00

Outcome and costs of a goal-oriented, model-based, active TDM service – Alexander Vinks

9:45

Combination chemotherapy - Monte-Carlo simulation: from PK/PD

               Relationships to clinical applications - George Drusano

10:30

Coffee

11:00

Applied Clinical PK 4

Getting Nonparametric Bayesian Posteriors – Roger Jelliffe
Multiple Model (MM) versions
Interacting Multiple Model (IMM) versions for very unstable patients

The structure of MM Bayesian dosage individualization and adjustment

12:00

Aminoglycoside ototoxicity - Roger Jelliffe

12:30

Introduction to Clinical Cases - Roger Jelliffe

            Planning initial MM aminoglycoside therapy
            Normal and reduced renal function

13:00

Lunch

14:30

Advanced Clinical PK 5

More clinical case histories - Roger Jelliffe
Planning initial vancomycin therapy
Planning initial digoxin therapy
A gentamicin patient with changing renal function
A tobramycin patient with changing renal function and changing clinical status
Digoxin and atrial fibrillation
            Why the literature says it is no good for conversion
            Why the literature is probably wrong
            Four interesting digoxin cases

16:30

End

 

Link to the PK/PD General Concepts program at the beginner - intermediate level